Vertex Pharmaceuticals Inc banner

Vertex Pharmaceuticals Inc
NASDAQ:VRTX

Watchlist Manager
Vertex Pharmaceuticals Inc Logo
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Watchlist
Price: 455.76 USD -1.1% Market Closed
Market Cap: $115.6B

Relative Value

The Relative Value of one VRTX stock under the Base Case scenario is hidden USD. Compared to the current market price of 455.76 USD, Vertex Pharmaceuticals Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VRTX Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

VRTX Competitors Multiples
Vertex Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.4B USD 9.6 29.3 22 23
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
407.9B USD 6.7 97.4 16 22.2
US
Amgen Inc
NASDAQ:AMGN
197.9B USD 5.4 25.7 14.8 14.8
US
Gilead Sciences Inc
NASDAQ:GILD
178.6B USD 6.1 21 13.1 16.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.4B USD 5.6 17.8 13.3 15.2
AU
CSL Ltd
ASX:CSL
70.5B AUD 3.2 35.8 11.8 14.8
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
NL
argenx SE
XBRU:ARGX
37.8B EUR 10.8 34.7 37.6 38.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
42.4B USD 11.4 135.2 75.3 83.7
P/S Multiple
Revenue Growth P/S to Growth
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Average P/S: 3 063 003.9
9.6
11%
0.9
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.4
3%
1.8
US
Gilead Sciences Inc
NASDAQ:GILD
6.1
5%
1.2
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
10%
0.6
AU
CSL Ltd
ASX:CSL
3.2
4%
0.8
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
NL
argenx SE
XBRU:ARGX
10.8
27%
0.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
11.4
33%
0.3
P/E Multiple
Earnings Growth PEG
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Average P/E: 49.6
29.3
16%
1.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
97.4
97%
1
US
Amgen Inc
NASDAQ:AMGN
25.7
20%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
21
16%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
13%
1.4
AU
CSL Ltd
ASX:CSL
35.8
10%
3.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
NL
argenx SE
XBRU:ARGX
34.7
32%
1.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
135.2
83%
1.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Average EV/EBITDA: 25.5
22
16%
1.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16
12%
1.3
US
Amgen Inc
NASDAQ:AMGN
14.8
10%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
13.1
9%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.3
18%
0.7
AU
CSL Ltd
ASX:CSL
11.8
7%
1.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
NL
argenx SE
XBRU:ARGX
37.6
50%
0.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
75.3
67%
1.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Average EV/EBIT: 28.5
23
16%
1.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.2
24%
0.9
US
Amgen Inc
NASDAQ:AMGN
14.8
3%
4.9
US
Gilead Sciences Inc
NASDAQ:GILD
16.2
13%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.2
23%
0.7
AU
CSL Ltd
ASX:CSL
14.8
10%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
NL
argenx SE
XBRU:ARGX
38.4
56%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
83.7
69%
1.2
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett